Business
Hardman Res. - Validating multiple opportunities
Hardman Res. - Validating multiple opportunities.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9320E Scancell Holdings Plc 15 February 2018 \n\nHardman Research - Validating multiple opportunities\nValidating and de-risking of multiple opportunities: Scancell is a clinical-stage biotechnology company developing two distinct flexible cancer immunotherapy platforms, each with broad applications: ImmunoBody is a DNA vaccine that stimulates high-avidity anti-tumour CD8+ T-cells for use as a monotherapy or in combination with checkpoint inhibitors (CPIs); Moditope targets modified antigens and stimulates powerful anti-tumour CD4+ T-cell responses for use in advanced and hard-to-treat cancers. Both technologies have been externally validated recently through partnership deals with Cancer Research UK (CRUK; ImmunoBody SCIB2) and BioNTech (Moditope), providing significant endorsements.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/scancell-documents/15.02.18-validating-and-de-risking-of-multiple-opportunities.pdf\n\n\n\n\nTo contact us:\nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\nwww.hardmanandco.com\nFollow us on Twitter @HardmanandCo\n\n\nContacts:\nDr Martin Hall\nDr Dorothea Hill\nDr Gregoire Pave\n\n+44 20 7194 7622\n\n\n \[email protected]@[email protected]\n\n\n\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticat...